Ken Reed

Dr. Ken Reed is a prominent dermatologist and the founder of DermASAP, known for his expertise in biotechnology, drug development, and clinical research.

He holds a Doctor of Medicine from the College of Medicine and Dentistry of New Jersey and completed his Dermatology Residency Program at Harvard Medical School, with additional training in Internal Medicine from Thomas Jefferson University.

Dr. Reed also pursued a Bachelor's Degree in Biology from Brown University, showcasing his strong foundation in the life sciences.

With a keen interest in cutting-edge medical technologies, Dr. Reed has served on the Scientific Advisory Boards of various biotech companies like Zen Graphene, Xylyx Bio, WinProbe, Mybiotix, and Bambu Global.

His entrepreneurial spirit led him to co-found companies such as Prescient Pharma LLC and EarlyCell, demonstrating his commitment to advancing innovative healthcare solutions.

Dr. Reed has also contributed his expertise as a Director at Minerva Biotechnologies and as a member of the Board of Directors at RedHill Biopharma Ltd. and Aquatic Treatment Systems.

His career in dermatology has been marked by his role as a Dermatologist at DermASAP and as the Co-Founder of Prescient Health Solutions, highlighting his dedication to providing quality care and advancing medical knowledge.

Passionate about research, Dr. Reed has delved into areas such as cell isolation techniques and noninvasive prenatal diagnostic testing, showcasing his diverse interests within the field of dermatology.

His extensive educational background, coupled with his entrepreneurial ventures and research endeavors, solidify Dr. Reed's reputation as a multifaceted professional in the medical and biotechnology industries.